AstraZeneca is one of the world’s most exciting bio-pharmaceutical companies. From scientists to sales, lab techs to legal we’re on a mission to turn ideas into life-changing medicines that improve patients’ lives and benefit society. We’re constantly moving forward as a company – agile and purposeful in our work. We are building a new kind of organisation, one that can improve the lives of 200 million patients and be a $50 billion company in 2025. This ambition drives us to continue to transform to be a bio-pharmaceutical company that pioneers new methods and adapts and evolves to pursue discoveries like no one else.
1800 Concord Pike, Wilmington, DE 19850
As we navigate current socio-economic and environmental challenges, we must prioritise building sustainable, resilient and equitable health systems that protect current and future generations. During 2022, AstraZeneca demonstrated its continued commitment to innovate for patients and improve health outcomes worldwide. Our pandemic response and global vaccine delivery are testament to this, with over six million lives saved in the first year1 and a focus on equitable access. We are making important progress with our science-led Ambition Zero Carbon strategy. By the end of December 2022, we had achieved a 59.3% reduction in Scope 1 and 2 greenhouse gas (GHG) emissions compared to our 2015 baseline, with our AZ Forest programme working in parallel to help restore nature and biodiversity, and over 10.5 million trees planted since 2020. We also continued to drive change across the health sector, including through the Sustainable Markets Initiative (SMI). Ahead of COP27, the SMI Health Systems Task Force, which I am honoured to champion, announced shared commitments and actions to reduce emissions in line with the 1.5°C pathway and accelerate the transition to net-zero health systems. Furthermore, the Partnership for Health System Sustainability and Resilience (PHSSR), which we co-founded in 2020, has now expanded to more than 30 countries. Our top three ranking in the 2022 Access to Medicine Index recognises our strategic focus on increasing equitable and affordable access to life-changing treatments. How we achieve results is of vital importance, and we are guided by our Values in all that we do. Through our Code of Ethics and standards, we strive for a safe, responsible and ethical business culture for our employees and partners. We also take pride in championing a culture of inclusion and belonging, recognising the power of diversity in fostering innovation. 2023 will see us further accelerate our efforts in delivering our sustainability goals. By working with others to prioritise health, we will play our part in ensuring communities and societies thrive, economies prosper, and the planet recovers.